Table 2.
Correlation analysis of ADAM12L, EGF-like ligands, and EGFR in breast tumors from the EMC286 cohort. Values represent Pearson r.
| All
| |||||||
|---|---|---|---|---|---|---|---|
| EGF | HB-EGF | TGFα | AREG | BTC | EREG | EGFR | |
| ADAM12L | −0.0525 (p = 0.3766) | 0.0603 (p = 0.3095) | −0.0781 (p = 0.1877) | 0.0432 (p = 0.4663) | −0.1097 (p = 0.0640) | 0.0278 (p = 0.6392) | 0.0067 (p = 0.9104) |
| ER+
| |||||||
|---|---|---|---|---|---|---|---|
| EGF | HB-EGF | TGFα | AREG | BTC | EREG | EGFR | |
| ADAM12L | −0.0520 (p = 0.4646) | −0.0068 (p = 0.9243) | −0.1431 (p = 0.0432) | 0.0019 (p = 0.9784) | −0.1141 (p = 0.1077) | 0.0258 (p = 0.7174) | 0.0203 (p = 0.7750) |
| ER−
| |||||||
|---|---|---|---|---|---|---|---|
| EGF | HB-EGF | TGFα | AREG | BTC | EREG | EGFR | |
| ADAM12L | −0.08296 (p = 0.4476) | 0.3038 (p = 0.0045) | −0.0214 (p = 0.8446) | 0.1193 (p = 0.2738) | −0.0497 (p = 0.6493) | 0.0006 (p = 0.9954) | 0.1703 (p = 0.1169) |
| TNBC
| |||||||
|---|---|---|---|---|---|---|---|
| EGF | HB-EGF | TGFα | AREG | BTC | EREG | EGFR | |
| ADAM12L | −0.1004 (p = 0.4744) | 0.3632 (p = 0.0075) | 0.0504 (p = 0.7202) | 0.2246 (p = 0.1060) | −0.1060 (p = 0.4500) | −0.0276 (p-0.8445) | 0.2728 (p = 0.0481) |
| non-TNBC
| |||||||
|---|---|---|---|---|---|---|---|
| EGF | HB-EGF | TGFα | AREG | BTC | EREG | EGFR | |
| ADAM12L | −0.1030 (p = 0.5685) | 0.2593 (p = 0.1450) | −0.2398 (p = 0.1789) | 0.0735 (p = 0.6843) | 0.1051 (p = 0.5605) | 0.1093 (p = 0.5448) | 0.1751 (p = 0.3297) |